Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.17179/excli2015-297 http://scihub22266oqcxt.onion/10.17179/excli2015-297 C4669907!4669907!26648823     free     free     free       EXCLI+J 2015 ; 14 (ä): 714-46 Nephropedia Template TP {{tp|p=26648823|t=2015. Short-interference RNAs: becoming medicines |pdf=|usr=}}{{26648823}} gab.com Text Short-interference RNAs: becoming medicines JO: EXCLI J http://www.kidney.de/pget.php?&tw=1&pmid=26648823 #FOAvip RNA interference is a cellular mechanism by which small molecules of double stranded RNA modulate gene expression acting on the concentration and/or availability of a given messenger RNA. Almost 10 years after Fire and Mello received the Nobel Prize for the discovery of this mechanism in flat worms, RNA interference is on the edge of becoming a new class of therapeutics. With various phase III studies underway, the following years will determine whether RNAi-therapeutics can rise up to the challenge and become mainstream medicines. The present review gives a thorough overview of the current status of this technology focusing on the path to the clinic of this new class of compounds. Twit Text FOAVip Short-interference RNAs: becoming medicines ????EXCLI J http://www.kidney.de/pget.php?&tw=1&pmid=26648823 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26648823 #FOAvip English Wikipedia <ref>{{Cite pmid|26648823}}</ref> Short-interference RNAs: becoming medicines #MMPMID26648823 Martínez T; Jiménez AI; Pañeda C EXCLI J 2015[]; 14 (ä): 714-46 PMID26648823show ga RNA interference is a cellular mechanism by which small molecules of double stranded RNA modulate gene expression acting on the concentration and/or availability of a given messenger RNA. Almost 10 years after Fire and Mello received the Nobel Prize for the discovery of this mechanism in flat worms, RNA interference is on the edge of becoming a new class of therapeutics. With various phase III studies underway, the following years will determine whether RNAi-therapeutics can rise up to the challenge and become mainstream medicines. The present review gives a thorough overview of the current status of this technology focusing on the path to the clinic of this new class of compounds. äShort-interference RNAs: becoming medicines (epmc).pdf DeepDyve Pubget Overpricing